1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunologic impact of anti-CTLA-4 therapy
    Meeting Abstract

    Sharma, P.; Tsavachidou, D.; Kamat, A.; Tang, D. N.; Chen, H.; Fu, T.; Troncoso, P.; Wolchok, J.; Logothetis, C. J.; Allison, J. P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Characteristics of first relapse in stage III melanoma patients with no evidence of disease (NED): Guidelines for follow-up
    Meeting Abstract

    Romano, E.; Scordo, M.; Chapman, P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • PLX4032, a highly selective (V600E)BRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial
    Meeting Abstract

    Puzanov, I.; Nathanson, K. L.; Chapman, P. B.; Xu, X.; Sosman, J. A.; McArthur, G. A.; Ribas, A.; Kim, K. B.; Grippo, J. F.; Flaherty, K. T.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
    Meeting Abstract

    O'Day, S.; Weber, J.; Lebbe, C.; Maio, M.; Pehamberger, H.; Harmankaya, K.; Siegel, J.; Hoos, A.; Humphrey, R.; Wolchok, J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM)
    Meeting Abstract

    Ott, P. A.; Carvajal, R. D.; Pandit-Taskar, N.; Jungbluth, A. A.; Hoffman, E.; Venhaus, R.; Pan, L.; Old, L.; Pavlick, A. C.; Wolchok, J. D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
    Meeting Abstract

    Lutzky, J.; Wolchok, J.; Hamid, O.; Lebbe, C.; Pehamberger, H.; Linette, G.; de Pril, V.; Ibrahim, R.; Hoos, A.; O'Day, S.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
    Meeting Abstract

    Flaherty, K.; Puzanov, I.; Sosman, J.; Kim, K.; Ribas, A.; McArthur, G.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT
    Meeting Abstract

    Carvajal, R. D.; Chapman, P. B.; Wolchok, J. D.; Cane, L.; Teitcher, J. B.; Lutzky, J.; Pavlick, A. C.; Bastian, B. C.; Antonescu, C. R.; Schwartz, G. K.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
    Meeting Abstract

    Berman, D. M.; Wolchok, J.; Weber, J.; Hamid, O.; O'Day, S.; Chasalow, S. D.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity
    Meeting Abstract

    Amin, A.; DePril, V.; Hamid, O.; Wolchock, J.; Maio, M.; Neyns, B.; Chin, K.; Ibrahim, R.; Hoos, A.; O'Day, S.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save